Latest News and Press Releases

MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting...

New preclinical RDT data show that DARPins can be engineered to increase tumor uptake as well as reducing accumulation in kidneys Engineering solutions transferrable across the platform and to a broad...

Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected...

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targeting efficiency and safety over historic...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens,...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort...